Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stake Boosted by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale lifted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 94.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 91,540 shares of the specialty pharmaceutical company's stock after buying an additional 44,414 shares during the period. DekaBank Deutsche Girozentrale owned about 0.15% of Jazz Pharmaceuticals worth $11,210,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in JAZZ. ST Germain D J Co. Inc. bought a new position in Jazz Pharmaceuticals during the second quarter valued at approximately $40,000. Covestor Ltd lifted its position in Jazz Pharmaceuticals by 676.5% during the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company's stock valued at $51,000 after purchasing an additional 345 shares during the period. Spire Wealth Management lifted its position in Jazz Pharmaceuticals by 128.6% during the third quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 238 shares during the period. Headinvest LLC bought a new position in Jazz Pharmaceuticals during the third quarter valued at approximately $56,000. Finally, Signaturefd LLC lifted its position in Jazz Pharmaceuticals by 85.7% during the third quarter. Signaturefd LLC now owns 546 shares of the specialty pharmaceutical company's stock valued at $71,000 after purchasing an additional 252 shares during the period. Institutional investors own 89.14% of the company's stock.

Insiders Place Their Bets

In other news, CAO Patricia Carr sold 1,936 shares of the firm's stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CAO Patricia Carr sold 1,936 shares of the firm's stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Philip L. Johnson bought 12,000 shares of the stock in a transaction dated Friday, March 1st. The stock was purchased at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. Corporate insiders own 4.40% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Barclays lowered their price objective on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an "overweight" rating on the stock in a research report on Friday, March 1st. Truist Financial reiterated a "buy" rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. HC Wainwright reduced their price objective on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a "buy" rating for the company in a research note on Thursday, March 14th. UBS Group reduced their price objective on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a "neutral" rating for the company in a research note on Friday, March 1st. Finally, Robert W. Baird started coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, January 3rd. They issued an "outperform" rating and a $160.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $195.08.

Jazz Pharmaceuticals Price Performance

JAZZ traded up $0.08 during trading on Wednesday, hitting $114.08. 716,659 shares of the company traded hands, compared to its average volume of 617,931. The company has a market cap of $7.19 billion, a PE ratio of 18.64, a P/E/G ratio of 1.59 and a beta of 0.59. The stock's 50-day simple moving average is $121.66 and its two-hundred day simple moving average is $123.44. Jazz Pharmaceuticals plc has a 1 year low of $111.25 and a 1 year high of $147.45. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts' consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1.01 billion. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.